Valeant (VRX) 'Conservative Base Case' Suggests 109% Upside - Nomura
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
UPDATE: Eventually Valeant (VRX) Fundamentals Will Matter Again - UBS
November 11, 2015 9:44 AM EST(Updated - November 11, 2015 9:49 AM EST)
(correction: price target is $255)
UBS analyst Marc Goodman reiterated a Buy rating and $255 price target on Valeant Pharmaceuticals (NYSE: VRX) following yesterday's business update. The analyst said eventually fundamentals will matter again. Goodman listed 6 takeaways from... More
JPMorgan Cuts PT on Valeant (VRX) to $225
November 11, 2015 6:42 AM ESTJPMorgan trims its price target on Valeant Pharma (NYSE: VRX) from $265 down to $225. The firm maintained its Overweight rating on Valeant
For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.
... MorePhilidor Rx Disappointed Relationship with Valeant (VRX) Has Ended
November 10, 2015 5:22 PM ESTPhilidor Rx said in a statement:
We have valued our close working relationship with Valeant (NYSE: VRX) and are deeply disappointed that is has come to an end. It is unfortunate that this outcome was influenced by market forces, media misperceptions, and inflammatory,... More
Valeant Pharma (VRX) Moves Solidly Into the Green, Erasing 7.5% Loss
November 10, 2015 2:01 PM ESTEmbattled Valeant Pharma (NYSE: VRX) has gone solidly positive territory mid-day after trading down as much as 7.5% earlier. Shares last traded at $85.63, up 0.3%. Upside is related to... More
Citron's Left Says Valeant Pharma (VRX) Short 'Significantly Scaled-Down' from Initial Position
November 10, 2015 12:33 PM ESTCitron's Andrew Left says short in Valeant Pharma (NYSE: VRX) is "significantly scaled down" from where it initially was.
... MoreMallinckrodt (MNK) is not Valeant Pharma (VRX) 'it's worse' - Left
November 10, 2015 12:27 PM ESTMallinckrodt (NYSE: MNK) is not Valeant Pharma (NYSE: VRX), "it's worse", Citron Research's Andrew Left says
... MoreValeant Pharma (VRX) CEO Pearson Says Company 'is Going to Survive'
November 10, 2015 9:25 AM ESTWith its conference call today, Valeant Pharma (NYSE: VRX) said it doesn't have contingency plans if the stock keeps falling and it will sustain a short-term hit in its dermatology business.
CEO Michael Pearson also the company "is going to survive" and... More
Drugmaker Valeant to feel sting of closing controversial pharmacy
November 10, 2015 8:26 AM ESTBy Euan Rocha and Rod Nickel
TORONTO/WINNIPEG (Reuters) - Valeant Pharmaceuticals International Inc (NYSE: VRX) (NYSE: VRX) said on Tuesday its dermatology business would be hurt in the short term as it moves rapidly to sever ties with a controversial specialty pharmacy.
As of last week, Philidor Rx Services has stopped handling insurance claims for drugs and it will cease operations by the end of January, Valeant Chief Executive Officer Mike Pearson told investors and analysts on a conference call on Tuesday.
The call, however,... More
